|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Burden of disease in older adults
Keynote Lecture by Stefan Gravenstein, Brown University
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Burden of disease in infants
Keynote Lecture by Simon Drysdale, St George's University Hospitals NHS Foundation Trust
|
ESWI Respiratory Virus Summit 2024
RSV: Testimonial from a Patient Perspective
From the ESWI Respiratory Virus Summit 2024
|
ESWI Respiratory Virus Summit 2024
Welcome By The Co-Chairs at the Respiratory Virus Summit 2024
From the ESWI Respiratory Virus Summit 2024
Is eradication of influenza B viruses possible?
Influenza B virus infections account for a substantial proportion of cases of influenza annually, with a high morbidity and mortality burden, especially in children (aged 0–18 years)
Call for expression of interest – Members representing non-governmental organisations in the Advisory Forum of the European Centre for Disease Prevention and Control
The European Commission has launched a call for expression of interest aiming at the selection of the ECDC Advisory Forum members. The deadline for submission of applications is 4 April 2024.
In Utero Exposure to Maternal COVID-19 Vaccination and Offspring Neurodevelopment at 12 and 18 Months
Uptake of COVID-19 vaccines among pregnant individuals was hampered by safety concerns around potential risks to unborn children.
Cryptic proteins translated from deletion-containing viral genomes dramatically expand the influenza virus proteome
Scientific Papers
Article
Influenza vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Society of Cardiology, the Portuguese Society of Diabetology, the Portuguese Society of Infectious Disea
Influenza affects millions of people worldwide each year and can lead to severe complications, hospitalizations, and even death, especially among vulnerable populations such as older adults and those with chronic medical conditions.
Evaluation of the effectiveness and impact of Nirsevimab in Galicia
The purpose of NIRSE-GAL is to evaluate the impact of the inclusion of nirsevimab in the Galician immunisation schedule on the prevention of Respiratory Syncytial Respiratory Syncytial Virus (RSV) infections in children.
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1
COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of the SARS-CoV-2 XBB.1.5 subvariant.